Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Extensive Alopecia Areata
NCT02599129Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in alopecia areata, sponsored by Icahn School of Medicine at Mount Sinai. Started Nov 2015; status: terminated.
02
Drugs
secukinumab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT02599129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599129.